Improvement of glycaemic control in type 2 diabetes: Favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, von Willebrand factor and (pro)insulin

Netherlands Journal of Medicine

Volumn 61, Issue 4, 2003, Pages 129-136

  Becker, A ^a   van der Does, F E E ^b   van Hinsbergh, V W M ^c   Heine, R J ^a,c   Bouter, L M ^a,c   Stehouwer, C D A ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO Prevention and Health ^*

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; CHOLESTEROL; CREATININE; FIBRINOGEN; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PROINSULIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CAPILLARY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DATA ANALYSIS; DIABETES CONTROL; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOSIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME;

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROINSULIN; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES; VON WILLEBRAND FACTOR;

EID: 0038448090     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672-6.
2. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 1997;350(suppl 1):S4-9.
3. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-9.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. Gilbert RE, Tsalamandris C, Bach LA, et al. Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney International 1993;44:885-9.
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
7. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-84.
8. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary, heart disease in elderly subjects. Diabetes 1994;43:960-7.
9. Moss SE, Klein R, Klein BEK, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473-9.
10. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9.
11. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999;16:2-13.
12. Vegt F de, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
14. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997;157:181-8.
15. Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 1992;15:1245-50.
16. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000;283:221-8.
17. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133:81-91.
18. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, Ottolander GJH den. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319-23.
19. Conlan MG, Folsom AR, Finch A, et al. Associations of Factor VII and von Willebrand Factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemostas 1993;70:380-5.
20. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
21. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736-41.
22. Beatty OL, Ritchie CM, Bell PM, Hadden DR, Kennedy L, Atkinson AB. Microalbuminuria as identified by a spot morning urine specimen in non-insulin-treated diabetes: an eight-year follow-up study. Diabet Med 1995;12:261-6.
23. MacLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995;38:610-6.
24. Jager A, Hinsbergh VW van, Kostense PJ, et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-8.
25. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:617-24.
26. Jager A, Hinsbergh VW van, Kostense PJ, et al. Prognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria. Nephrol Dial Transplant 2001;16:529-36.
27. Cromme PVM, Mulder JD, Rutten GEHM, Zuidweg J, Thomas S. NHG-Standaard Diabetes mellitus type II. In: Rutten GEHM, Thomas S (eds.). Utrecht: Nederlands Huisartsen Genootschap, 1993.
28. Does FE van der, Neeling JN de, Snoek FJ, et al. Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. Diabetes Care 1998;21:2085-93.
29. Bowsher RR, Wolny JD, Frank BH. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum. Diabetes 1992;41:1084-90.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31. Ingerslev JA. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest 1987;47:143-9.
32. Tranquille N, Emeis JJ. The simultaneous acute release of tissue-type plasminogen activator and von Willebrand factor in the perfused rat hindleg region. Thromb Haemostas 1990;63:454-8.
33. Poppel MN van, Koes BW, Deville W, Smid T, Bouter LM. Risk factors for back pain incidence in industry: a prospective study. Pain 1998;77:81-6.
34. Gatling W, Knight C, Mullee MA, Hill RD. Microalbuminuria in diabetes: a population study of the prevalence and an assessment of three screening tests. Diabetic Med 1988;5:343-7.
35. Knöbl P, Schernthaner G, Schnack C, et al. Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thrombosis Haemostasis 1994;71:692-7.
36. Knaap JH v/d, Boer AC de, Pannebakker MAG, Heerde W van, Ottolander GJH den. The effect of diabetes regulation on platelet release, fibrinolysis and coagulation tests, before and after stimulation with DDAVP. Thromb Haemostas 1985;53:118-21.
37. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000;43:1099-106.
38. Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995;47:1703-20.
39. Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23:1478-85.
40. Boever E de, Bacquer D de, Braeckman L, Baele G, Rosseneu M, Backer G de. Relation of fibrinogen to lifestyles and to cardiovascular risk factors in a working population. Int J Epidemiol 1995;24:915-21.
41. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
42. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
43. Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 1998;158:2485-90.
44. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996;124(1 pt 2):110-6.
45. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998;97:996-1001.
46. Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Relation with hyperinsulinemia and the metabolic syndrome. Arterioscler Thromb Vasc Biol 1995;15:2229-33.
47. Feo P de, Gaisano MG, Haymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest 1991;88:833-40.
48. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1-7.
49. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of Plasminogen Activator Inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemostas 1988;60:491-4.
50. Kooistra T, Bosma PJ, Töns HAM, Berg AP van den, Meyer P, Princen HMG. Plasminogen Activator Inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989;62:723-8.
51. Jeejeebhoy KN, Ho J, Greenberg GR, Phillips MJ, Bruce-Robertson A, Sodtke U. Albumin, fibrinogen and transferrin synthesis in isolated rat hepatocyte suspensions: a model for the study of plasma protein synthesis. Biochem J 1975;146:141-5.
52. Thompson D, Harrison SP, Evans SW, Whicher JT. Insulin modulation of acute-phase protein production in a human hepatoma cell line. Cytokine 1991;3:619-26.
53. Grieninger G, Plant PW, Liang TJ, et al. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann NY Acad Sci 1983;408:469-89.